A Comprehensive Investigation of the Interactions between Proteins and Ligands in the Crystal Structures of Mycobacterium Tuberculosis

References (64)

1. 1 A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis [DOI]
2. 2 A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis [DOI]
3. 3 Advances in the development of new tuberculosis drugs and treatment regimens [DOI]
4. 4 The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis [DOI]
5. 5 PDBsum: a web-based database of summaries and analyses of all PDB structures [DOI]
6. 6 Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis [DOI]
7. 7 Diagnosis and Treatment of Extrapulmonary Tuberculosis [DOI]
8. 8 The association between sterilizing activity and drug distribution into tuberculosis lesions [DOI]
9. 9 The Clinical Pharmacokinetics of Levofloxacin [DOI]
10. 10 Drug Resistance Mechanisms in Mycobacterium tuberculosis [DOI]
11. 11 Rifampin: Mechanisms of Action and Resistance [DOI]
12. 12 Towards a new combination therapy for tuberculosis with next generation benzothiazinones [DOI]
13. 13 Levofloxacin [DOI]
14. 14 History of the Development of Rifampin [DOI]
15. 15 Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit [DOI]
16. 16 Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis [DOI]
17. 17 Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis [DOI]
18. 18 Treatment of Tuberculosis. A Historical Perspective [DOI]
19. 19 Tmc207: the First Compound of A New class of Potent Anti-Tuberculosis Drugs [DOI]
20. 20 Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model [DOI]
21. 21 Laboratory Diagnosis of Extra-pulmonary Tuberculosis (EPTB) in Resource- constrained Setting: State of the Art, Challenges and the Need [DOI]
22. 22 Delamanid: First Global Approval [DOI]
23. 23 Advances in the diagnosis of tuberculosis [DOI]
24. 24 Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis [DOI]
25. 25 Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin [DOI]
26. 26 Approval of Novel TB Drug Celebrated—With Restraint [DOI]
27. 27 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis [DOI]
28. 28 Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis [DOI]
29. 29 Crystal Structure of the Pyrazinamidase of Mycobacterium tuberculosis: Insights into Natural and Acquired Resistance to Pyrazinamide [DOI]
30. 30 Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis [DOI]
31. 31 Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824 [DOI]
32. 32 Mycobacterium tuberculosis Folate Metabolism and the Mechanistic Basis for para -Aminosalicylic Acid Susceptibility and Resistance [DOI]
33. 33 Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives [DOI]
34. 34 Levofloxacin: a therapeutic review [DOI]
35. 35 The Protein Synthesis Inhibitors, Oxazolidinones and Chloramphenicol, Cause Extensive Translational Inaccuracy in Vivo [DOI]
36. 36 The role of moxifloxacin in tuberculosis therapy [DOI]
37. 37 Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy [DOI]
38. 38 SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development [DOI]
39. 39 In VivoAntibacterial Activity of MRX-I, a New Oxazolidinone [DOI]
40. 40 Structure of a quinolone-stabilized cleavage complex of topoisomerase IV fromKlebsiella pneumoniaeand comparison with a relatedStreptococcus pneumoniaecomplex [DOI]
41. 41 Structure-Based Optimization of Pyridoxal 5′-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis [DOI]
42. 42 Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. [DOI]
43. 43 Levofloxacin [DOI]
44. 44 Crystal Structures of Wild-Type p-Hydroxybenzoate Hydroxylase Complexed with 4-Aminobenzoate, 2,4-Dihydroxybenzoate, and 2-Hydroxy-4-aminobenzoate and of the Tyr222Ala Mutant Complexed with 2-Hydroxy-4-aminobenzoate. Evidence for a Proton Channel and a New Binding Mode of the Flavin Ring [DOI]
45. 45 Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers [DOI]
46. 46 Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor [DOI]
47. 47 Current trends in chemotherapy of tuberculosis.
48. 48 Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin? [DOI]
49. 49 Drug use evaluation of moxifloxacin (avelox) using a hand-held electronic device at a canadian teaching hospital.
50. 50 The Minasarc study: A case-control study measuring mineral exposome in sarcoidosis [DOI]
51. 51 Global tuberculosis report (2014)
52. 52 A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker) [DOI]
53. 53 Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies [DOI]
54. 54 Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol [DOI]
55. 55 Evolution of rifampicin treatment for tuberculosis [DOI]
56. 56 Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824) [DOI]
57. 57 The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis [DOI]
58. 58 Structural insights into species-specific features of the ribosome from the human pathogen Mycobacterium tuberculosis [DOI]
59. 59 Rox, a Rifamycin Resistance Enzyme with an Unprecedented Mechanism of Action [DOI]
60. 60 Pretomanid for tuberculosis treatment: an update for clinical purposes [DOI]
61. 61 Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model [DOI]
62. 62 Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli [DOI]
63. 63 Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan [DOI]
64. 64 Primary Lung Tuberculosis

Cited by 0

No indexed citations yet.

Related research

• Extrapulmonary Tuberculosis of the Genitourinary System — shares topic coverage
• The Prevalence of Tuberculosis among BCG Vaccinated Individuals at the North West Region of Cameroon — shares topic coverage
• Bacterial and Fungal Contaminants in Mycobacterium tuberculosis Cultures at National Tuberculosis Referral Laboratory-Kampala — shares topic coverage
• Patterns of Initial Drug Resistance of Mycobacterium tuberculosis Isolates from Kashmir Valley, India — shares topic coverage
• Analyzing Different Acetyl Co-A Metabolizing Enzymes as Potential Drug Targets against Mycobacterium tuberculosis — shares topic coverage